Patent US6284458B1 successfully refreshed from Google Patents.
US6284458B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods for treatment of hepatitis C virus-associated diseases
Assignee: JURIDICAL FOUNDATION CHEMO-SERO-THERAPEUTIC RESARCH INSTITUTE
•
Filing: 1993-09-10
•
Granted: 2001-09-04
•
Expires: 2013-09-10
Abstract
Abstract Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
Inventors
- 👤 Kevin P. Anderson
- 👤 Ronnie C. Hanecak
- 👤 Kazuya Hoshiko
- 👤 Chikateru Nozaki
- 👤 Tsukasa Nishihara
- 👤 Hiroshi Nakatake
- 👤 Fukusaburo Hamada
- 👤 Tatsuo Eto
- 👤 Shinichi Furukawa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 18:13
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; A; A61; A61P; A61P31/00; A61P31/12; C07; C07H; C07H21/00; C07K; C07K14/00; C07K14/005; C12Q; C12Q1/00; C12Q1/70; C12Q1/701; C12Q1/706; C12Q1/707; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/33; C12N2310/35; C12N2310/352; C12N2310/3521; C12N2310/3527; C12N2770/00; C12N2770/00011; C12N2770/24011; C12N2770/24211; C12N2770/24222
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
60 words
An oligonucleotide which has a nucleotide sequence complementary to at least a portion of a 5′ end untranslated region, polyprotein translation initiation codon region or core protein coding region of HCV genomic or messenger RNA, said oligonucleotide inhibiting the function of said RNA and selected from the group consisting of SEQ ID NOs: 1, 2, 4-8, 14, 16, and 21-24.
Claim 2
Dependent Claim
60 words
An oligonucleotide which has a nucleotide sequence complementary to at least a portion of a 5′ end untranslated region, polyprotein translation initiation codon region or core protein coding region of HCV genomic or messenger RNA, said oligonucleotide inhibiting the function of said RNA and selected from the group consisting of SEQ ID NOs: 1, 2, 4-8, 14, 16, and 21-24.
Claim 3
Dependent Claim
10 words
The oligonucleotide of claim 1 in a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
35 words
A method for inhibiting the activity of Hepatitis C virus comprising contacting the virus or cells infected with the virus with an oligonucleotide of claim 1 so that activity of Hepatitis C virus is inhibited.
Claim 5
Dependent Claim
14 words
The method of claim 3 wherein said oligonucleotide is in a pharmacuetically acceptable carrier.
Claim 6
Dependent Claim
32 words
The method of claim 3 wherein said oligonucleotide has a universal base at a position which is complementary to a nucleotide in the HCV RNA which is variable among strains of HCV.
Claim 7
Dependent Claim
11 words
The method of claim 5 wherein the universal base is inosine.
References Cited (Backward Citations)
EP0318216A1
Cited
US5714596A
Cited
EP0388232A1
Cited
WO1992019743A2
Cited
US5610054A
Cited
US5922857A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2004-09-03 | 2005-03-05 | 2005-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2008-09-03 | 2009-03-05 | 2009-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2012-09-03 | 2013-03-05 | 2013-09-04 | $7700.00 | Window Closed / Lapsed |